Congressional members question whether ESRD payment bundle may be hurting innovation

Several members of Congress are questioning whether innovation in kidney care is being hampered by the Medicare bundled payment rate for end-stage kidney disease treatment.
“As co-chairs of the Congressional Kidney and Health Care Innovation Caucuses, we share your goal of improving care and expanding access to innovative drugs and devices for patients with kidney diseases,” U.S. Reps. Suzan DelBene, D-Wash., Larry Bucshon, MD, R-Ind., and Ami Bera, MD, D-Calif., wrote in a recent letter to CMS Administrator Chiquita Brooks-LaSure. “To that end, we are encouraged that the

Several members of Congress are questioning whether innovation in kidney care is being hampered by the Medicare bundled payment rate for end-stage kidney disease treatment.
“As co-chairs of the Congressional Kidney and Health Care Innovation Caucuses, we share your goal of improving care and expanding access to innovative drugs and devices for patients with kidney diseases,” U.S. Reps. Suzan DelBene, D-Wash., Larry Bucshon, MD, R-Ind., and Ami Bera, MD, D-Calif., wrote in a recent letter to CMS Administrator Chiquita Brooks-LaSure. “To that end, we are encouraged that the